India Limits Markups on Critical Cancer Medicines to Protect Families from Financial Ruin

2026-10-24 global

New Delhi, Saturday, 24 October 2026.
Prompted by Supreme Court scrutiny exposing extreme retail markups over 700%, India has capped profit margins at 30% across 137 cancer drugs, slashing prices by up to 70% starting November 2026.

Supreme Court Provokes Government Action After Exposing Extortionate Markups

The catalyst for India’s sweeping intervention arrived on 29 September 2026, when a two-judge bench of the Supreme Court—justices Vikram Nath and Sandeep Mehta—held a marathon hearing on excessive retail markups in the oncology drug supply chain. During the proceedings, the court scrutinized documented cases where a medicine purchased at ₹2,700 ($33) by hospitals and retailers was resold to patients at ₹27,000 ($328), a markup exceeding 900% [1][3][4]. The justices labeled such pricing structures ‘extortion’ and ‘carnage,’ prompting an immediate government response [1]. This judicial pressure followed a five-year public-interest litigation filed by the advocacy group Jan Swasthya Abhiyan, which had demanded equitable pricing across all non-patented essential medicines [3].

Price Caps Introduced After Years of Inaction

India’s regulatory response arrived on 17 October 2026, when the National Pharmaceutical Pricing Authority (NPPA) invoked Paragraph 19 of the Drugs (Prices Control) Order, 2013 to impose a uniform 30% trade-margin cap on 137 non-scheduled anti-cancer drugs [3][5]. The move represents an expansion of a 2019 pilot program that had capped margins at 30% for just 42 cancer medications, generating estimated annual savings of ₹984 crore ($119 million) for patients [3][5]. Under the new rules, maximum retail prices are projected to fall by up to 70%, translating to annual savings of approximately ₹2,500 crore ($303 million) across the oncology sector [1][3][4]. The government notification followed Supreme Court directives issued on 29 September 2026, ending an 18-day period of judicial urgency [3].

Patient Advocacy and Human Cost Behind the Policy Shift

The legal saga traces back to 2021, when former bank employee Sarojam Radhakrishnan in Kerala was diagnosed with breast cancer and faced monthly treatment costs exceeding ₹63,000 ($763) [1]. Unable to afford care, she filed a public-interest petition in 2022 demanding government intervention to curb drug prices [1]. Her case gained tragic urgency in September 2022, when she passed away while the litigation was still pending [1]. Her story exemplifies a broader crisis: according to the Public Health Foundation of India, healthcare spending drives an estimated 55 million Indians below the poverty line annually [1]. Dr. Ravi Kannan, surgical oncologist and director of Cachar Cancer Hospital in Assam, described how families often initiate treatment but abandon chemotherapy or radiation due to unaffordable costs, leaving patients in medical limbo [1].

Market Impact and Supply-Chain Transparency Concerns

For multinational pharmaceutical companies and global healthcare investors, the 30% margin cap introduces significant downward pressure on operating margins across India’s emerging-market distribution networks [1]. The revised price list covers more than 20 cancer types, including breast, prostate, colon, ovarian, and cervical cancers, and includes high-cost biologics such as Pembrolizumab, Durvalumab, Osimertinib, Denosumab, and Bevacizumab [2]. Despite the price reductions, experts warn that medicine affordability does not equate to comprehensive cancer care. Hospital bills, diagnostic tests, and surgical fees can still total lakhs of rupees, leaving families vulnerable to catastrophic expenses [4]. Jyotsna Singh, co-convener of the Working Group on Access to Medicines and Treatments, emphasized the need for transparency across the entire supply chain—from manufacturing to point of sale—to ensure equitable access [1]. Krishan Kalra, former council member of the Rajiv Gandhi Cancer Institute, noted that many patients avoid early screening due to fear of unaffordable treatment, choosing to remain in the dark rather than confront potential financial ruin [1].

Implementation Timeline and Future Regulatory Outlook

The NPPA has scheduled the revised price caps to take effect on 9 November 2026, with manufacturers, retailers, and hospitals directed to comply immediately [2][3][5]. Patients are advised to verify updated prices using the government’s Pharma Sahi Daam mobile application to avoid overcharging [4]. Meanwhile, the Supreme Court has set a deadline of 27 October 2026 for the government to explain why the new caps apply only to cancer drugs and not to all non-patented medicines, raising the prospect of broader price controls in the future [1]. The Department of Pharmaceuticals has projected that the intervention could reduce medicine prices by up to 70% and help save patients ₹2,500 crore annually, significantly reducing out-of-pocket expenditures [1][3].

Sources

Healthcare regulation Pharmaceutical pricing